{
    "organizations": [],
    "uuid": "ae600eb198ded929d239f4b0300e586987803c61",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-tetraphase-pharmaceuticals-says-fd/brief-tetraphase-pharmaceuticals-says-fda-accepted-nda-filing-for-ciai-treatment-eravacycline-idUSASB0C7PD",
    "ord_in_thread": 0,
    "title": "BRIEF-Tetraphase Pharmaceuticals Says FDA Accepted NDA Filing For cIAI Treatment Eravacycline",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Tetraphase Pharmaceuticals Inc:\n* TETRAPHASE PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR FILING OF ITS NDA SUBMISSION FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)\n* TETRAPHASE PHARMACEUTICALS INC - PDUFA GOAL DATE FOR COMPLETION OF FDAâ€˜S REVIEW OF ERAVACYCLINE NDA IS SET FOR AUGUST 28, 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-27T21:14:00.000+02:00",
    "crawled": "2018-02-28T13:12:49.065+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "tetraphase",
        "pharmaceutical",
        "inc",
        "tetraphase",
        "pharmaceutical",
        "announces",
        "fda",
        "acceptance",
        "filing",
        "nda",
        "submission",
        "eravacycline",
        "treatment",
        "complicated",
        "infection",
        "ciai",
        "tetraphase",
        "pharmaceutical",
        "inc",
        "pdufa",
        "goal",
        "date",
        "completion",
        "fda",
        "review",
        "eravacycline",
        "nda",
        "set",
        "august",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}